GU Oncology Now

🔬 Data from a recent multicenter study revealed that patients with high-risk non-clear cell RCC exhibit comparable 5-year cancer-specific and overall survival outcomes compared with ccRCC. 👉 These findings highlight that patients with nccRCC may benefit from adjuvant therapy, potentially enhancing long-term survival rates:

📺 In the second part of our NMIBC roundtable, the panelists address the increasing availability of intravesical and systemic therapies, the importance of accurate risk stratification, and the role of education for both health care providers and patients:

👉 AstraZeneca's #durvalumab has been granted Priority Review by the FDA for the treatment of patients with muscle-invasive #bladdercancer. 🔬 This decision is based on data from the phase 3 NIAGARA trial, which demonstrated a statistically significant and clinically meaningful improvement in EFS and OS for patients receiving perioperative #durvalumab in combination with standard therapies:

⚙️ Presented at #SUO24, Jesse Persily, MD, and fellow researchers from NYU Langone Health have developed and externally validated a machine learning model to determine renal function after nephrectomy, which was found to outperform previous benchmark datasets:

📺 We spoke with Roger Li on his recent research which focused on oncolytic #immunotherapy with #nivolumab for MIBC. 👉 This innovative neoadjuvant regimen targets micrometastatic disease in patients with both non-muscle invasive and muscle-invasive bladder cancer, showing efficacy on par with cisplatin-based chemotherapy: https://buff.ly/4ivPeOG

❗️ The oncolytic immunotherapy drug cretostimogene grenadenorepvec has demonstrated groundbreaking results for the treatment of HR BCG-unresponsive NMIBC based on new topline data from the phase III BOND-003 trial. 👉 The CG Oncology treatment received Fast Track and Breakthrough Therapy designations by the FDA in December 2023:

⭐ Dr. Gordon Brown of Summit Health leads a roundtable discussion featuring Drs. Tim Richardson, Bryan Mehlhaff of Oregon Urology Institute, Christopher Pieczonka, and Eugene Cone of Urology of Indiana LLC. 📺 Watch the first part of their discussion, which focuses on the evolving landscape of NMIBC, focusing on patient identification, risk stratification, operational challenges in clinical practice, and emerging therapeutic options: https://buff.ly/3OO4NmV

👉 New data from #SUO24 has shed light on the prognostic value of ctDNA in patients with pN+ lymph nodes following robotic-assisted radical cystectomy with ePLND. 🔎 The findings highlight ctDNA as a robust biomarker for RFS and its potential role in refining treatment strategies for muscle-invasive bladder cancer:

🧪 A recent real-world analysis provides data on treatment patterns, biomarker testing, and clinical outcomes for patients with #mCRPC harboring HRRm treated with #olaparib monotherapy. 👉 Learn how olaparib affects patients with germline or somatic mutations in key HRR genes, including BRCA1, BRCA2, ATM, and others:

📺 Watch Regina Barragán Carrillo discuss her latest paper on updates in the field of metastatic renal cell carcinoma. 👉 Fellow authors Toni Choueiri, Renee Maria Saliby, Tom Powles, Elizabeth Plimack, Eddy Saad, MD, MSc, and Laurence Albiges contributed to the review, which includes a comprehensive guide on selecting first and second-line treatments for mRCC: https://buff.ly/49pNS3J